TGA · AHPRA · FSANZ · ACCC

Last reviewed: September 2025

Aesthetic & Cosmetic Clinic Advertising Compliance Australia 2025 — TGA · AHPRA · ACCC

1. Regulatory framework for aesthetic clinic advertising

Aesthetic clinics operate at the intersection of three regulatory frameworks that each apply independently — and each has its own enforcement agency.

What makes aesthetic clinic compliance uniquely high-risk is that the TGA violation is criminal — advertising Schedule 4 medicines to consumers is not a civil penalty matter. It is an offence under the Therapeutic Goods Act punishable by imprisonment. A clinic's marketing team may not understand they are doing something criminal when they post "anti-wrinkle injections from $12/unit" on Instagram.

AHPRA assessed 775 advertising complaints in 2024–25 — up 104% in two years. Aesthetic and cosmetic clinics are one of the highest complaint-volume sectors.

2. The injectable advertising ban — TGA s.42DL

Section 42DL of the Therapeutic Goods Act 1989 creates an absolute criminal prohibition on advertising Schedule 4 (prescription-only) or Schedule 8 (controlled) medicines to the general public. Cosmetic injectables — including all botulinum toxin products and most dermal fillers — are Schedule 4 substances.

All of the following are prohibited under TGA s.42DL:

Brand names: Botox, Dysport, Xeomin, Juvederm, Restylane, Sculptra, Profhilo, Belotero, Radiesse

Generic names: botulinum toxin, hyaluronic acid filler, poly-L-lactic acid, calcium hydroxylapatite

Common nicknames used in advertising: anti-wrinkle injections, wrinkle relaxers, dermal fillers, lip fillers, cheek filler, jaw slimming, brow lift injections

Hashtags: #botox, #antiwrinkle, #dermalfillers, #lipfiller, #jawslimming

Implied references: "our signature injectable", "the treatment everyone's asking about", "our most popular procedure" where the context makes it clear that an injectable is meant

Pricing: "$12/unit", "fillers from $650", "jawline from $800" — injectable pricing in consumer-facing advertising is prohibited because listing a price implies advertising the product

What clinics can advertise instead:

• Cosmetic consultation services
• General facial aesthetic services ("facial rejuvenation", "non-surgical facial treatments")
• Practitioner credentials and approach
• Clinic environment and patient experience
• The outcome category without naming the mechanism ("a more rested appearance", "subtle facial contouring")

The prohibition extends to booking pages, pricing guides, service menus, and PDFs accessible to consumers — not just external advertising channels.

3. AHPRA before/after rules (2025)

AHPRA's advertising guidelines, reinforced in 2025, set strict requirements for before/after comparison imagery in cosmetic procedure advertising. Before/after images are not automatically banned — but they are only permitted when every one of the following conditions is met simultaneously:

Absolutely prohibited in before/after content:

• AI-generated or digitally predicted results
• Another clinic's or practitioner's patient photos
• Sexualised imagery
• Entertainment-style content (music montages, dancing reels, "satisfying" procedure videos)
• Emojis placed on or in response to outcome images

4. Patient testimonials — the absolute prohibition

Section 133(1)(c) of the National Law prohibits testimonials or purported testimonials about the clinical aspects of a regulated health service. For aesthetic clinics, this prohibition is broad.

Prohibited testimonial content:

• Google reviews mentioning treatment outcomes shared in clinic advertising
• Instagram posts by patients describing results ("My lips look amazing after my filler")
• Video testimonials from patients about their treatment or recovery
• Reposts of patient before/after selfies with outcome commentary
• Influencer posts describing treatment outcomes where the influencer received payment or free treatment

What is NOT a testimonial (generally permitted):

• Patient comments about parking, waiting times, or staff friendliness that contain no clinical reference
• General clinic ambience reviews that reference no clinical outcome
• Practitioners describing their own qualifications, training, or approach

Influencer note: Where a clinic provides free treatment or payment to an influencer in exchange for posting about their results, that post is a testimonial under s.133(1)(c) and the practitioner is responsible for its compliance — even if the influencer posts independently.

5. Compliant vs non-compliant examples

6. Social media, influencer, and pricing compliance

Social media (2025 requirements):

• All posts about higher-risk cosmetic procedures must be tagged as adult content on platform
• Must not target or direct advertising at people under 18 through demographic targeting
• Entertainment-style content — music montages, dancing while injecting, "satisfying" procedure reels — is prohibited for higher-risk procedures
• Emojis placed on or in response to outcome images are prohibited

Influencer marketing: Briefing an influencer to post about cosmetic treatments creates advertising that you are responsible for. Before any influencer arrangement:

• Confirm the influencer will not name or imply Schedule 4 products
• Provide permitted language and prohibited terms in writing
• Review content before it is posted wherever possible

Pricing: Two separate rules apply to clinic pricing:

• TGA s.42DL: Pricing for injectables ("$12/unit", "filler from $650") is prohibited in consumer-facing advertising — it implies advertising the Schedule 4 product
• ACL: All "from $X" pricing must reflect a genuinely achievable minimum — not a theoretical floor that no patient pays. "Cosmetic consultations from $80" where most patients pay $250 minimum is a misleading representation under ACL s.29

7. Common compliance mistakes

MISTAKE — Posting injectable hashtags on social content PROBLEM — Hashtags including #botox, #antiwrinkle, #dermalfillers, #lipfiller on clinic social accounts are TGA s.42DL breaches regardless of whether the post itself names the treatment. The hashtag alone constitutes an advertisement for a Schedule 4 substance. FIX — Remove all injectable-related hashtags from clinic social accounts. Use category hashtags: #facialrejuvenation, #aestheticmedicine, #cosmeticconsultation.

MISTAKE — Reposting patient testimonials as social proof PROBLEM — Reposting a patient's Google review or Instagram tag that describes their treatment outcome is a testimonial breach under s.133(1)(c) — even if the patient posted it voluntarily. The moment the clinic reposts or amplifies it, the clinic is responsible. FIX — Do not repost, share, or otherwise amplify any patient content that references a clinical outcome. Comments about parking, staff, or clinic environment are lower-risk.

MISTAKE — Including injectable service menus on the website PROBLEM — A services page or booking system listing "Lip Filler — from $650 per syringe" or "Anti-wrinkle injections — 1 area from $199" is consumer-facing advertising for Schedule 4 products. Placing it behind a form, a PDF download, or a "request pricing" button does not remove the TGA liability. FIX — Remove injectable pricing and service names from all consumer-accessible website pages. Gate detailed treatment information behind a verified consultation booking.

8. How CompliGUARD automates this check

CompliGUARD reviews aesthetic clinic marketing content — social captions, website service pages, email promotions, booking page copy, and influencer briefs — against TGA · AHPRA · ACCC simultaneously. Every review identifies injectable name or nickname references (including implied references and hashtags), before/after image compliance obligations, testimonial content, and outcome guarantee claims. Each review returns a clause-cited report, a risk rating, and a compliant rewrite. Every review is stored in a tamper-evident audit vault — evidence of due diligence before publication.

9. Penalty reference

10. Pre-publish checklist

TGA — Injectable advertising ban

AHPRA — Before/after and testimonials

AHPRA — Social media (2025)

ACCC / ACL

11. Key takeaways

1. Advertising Schedule 4 cosmetic injectables by brand name, generic name, nickname, hashtag, or implied reference to consumers is a criminal offence under TGA s.42DL — this includes injectable pricing in consumer-facing content.
2. Patient testimonials referencing clinical outcomes are absolutely prohibited under s.133(1)(c) of the National Law — this extends to reposted Google reviews, patient Instagram tags, and influencer posts.
3. Before/after images are only permitted when all six AHPRA conditions are met simultaneously — genuine patient, unedited, identical conditions, equal prominence, outcomes disclaimer, separate consent.
4. Influencer content briefed or compensated by the clinic is the clinic's advertising — TGA and AHPRA compliance obligations apply to that content.
5. Injectable pricing in any consumer-facing format — website, PDF, booking system — is an extension of the injectable advertising ban.

12. Related guides

→ Telehealth Advertising Compliance → Naturopath & Allied Health Advertising Compliance → What free tools do the TGA and AHPRA provide? → What does AHPRA's ban on testimonials actually cover?

13. Regulatory references

• Therapeutic Goods Act 1989 (Cth), s.42DL (prohibited advertisements — scheduled medicines)
• Health Practitioner Regulation National Law Act 2009, s.133(1)(c) (testimonial prohibition)
• AHPRA Advertising Guidelines, December 2020 (as updated 2025), §§4–6
• Therapeutic Goods Advertising Code 2021 (Cth), s.17 (testimonial restrictions)
• Australian Consumer Law (Schedule 2, Competition and Consumer Act 2010), ss.18, 29, 32

CompliGUARD provides compliance insights based on TGA, FSANZ, ACCC and AHPRA guidance as current at the time of review. The Therapeutic Goods Advertising Code is currently under formal review by the TGA (2025–26). This output does not constitute legal advice.